Skip to content

Standardization of Anti-Seizure Medications Withdrawals After Seizure Remission in Young Patients With Epilepsy

Anti-Seizure Medications Withdrawals After 2 Years of Seizure Remission

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05740423
Acronym
ADORE
Enrollment
1200
Registered
2023-02-23
Start date
2021-08-30
Completion date
2024-12-31
Last updated
2023-02-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy, Epilepsy in Children

Brief summary

The proper period of anti-seizure medication (ASM) treamtment is important for decreasing side effect of ASM and recurrence of seizure. We evaluate reliable risk factor analysis for safe withdrawal of ASM in children with epilepsy. Futhermore, we develop the scoring system for prediction of seizure recurrence to set the standard for safe withdrawal of ASM.

Detailed description

The proper period of anti-seizure medication (ASM) treamtment is important for decreasing side effect of ASM and recurrence of seizure. We evaluate reliable risk factor analysis for safe withdrawal of ASM in children with epilepsy. Futhermore, we develop the scoring system for prediction of seizure recurrence to set the standard for safe withdrawal of ASM. The enroll criteria as follow: 1. patients with epilepsy or acute provoked seizure accroding to the ILAE definition 2. patients who have been 2 years of seizure free with or without ASM The patients with seizure recurrence during follow-up or end of follow-up period of 24 months will end this stutdy.

Interventions

None listed

Sponsors

Ministry of Health, Republic of Korea
CollaboratorOTHER_GOV
Korea Health Industry Development Institute
CollaboratorOTHER_GOV
Asan Medical Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 18 Years
Healthy volunteers
No

Inclusion criteria

* Patients with Epilepsy or acute provoked seizure according to the ILAE guideline * Patients with 2 years of seizure free periods

Exclusion criteria

* Uncertain diagnosis of epilepsy or acute provoked seizure * Patients who do not want to participate in the study

Design outcomes

Primary

MeasureTime frameDescription
Patients umber of seizure recurrenceUp to 2 yearsPatients umber of seizure recurrence

Countries

South Korea

Contacts

Primary ContactMin-Jee Kim
pradoxwh@naver.com821045204711
Backup ContactMin-Sun Yum
misun.yum@gmail.com+82230103386

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026